StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The trial met significant endpoints despite being down overall. Fast Track designation adds potential for quicker approvals.
What happened, with direct paths to the underlying reporting
ARVN and PFE announced Phase 3 VERITAC-2 trial results for vepdegestrant. The trial met its primary endpoint for estrogen receptor 1-mutant patients. Overall survival results are not mature yet & will be assessed further. ARVN's stock down 52.4% at $8.35 post-announcement. FDA granted Fast Track designation for vepdegestrant earlier this year.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.